IND and NDA Applications in India

In India, the regulatory authority responsible for the approval of new drugs is the Central Drugs Standard Control Organization (CDSCO), under the Ministry of Health and Family Welfare. Similar to the United States, India also has two primary application types for drug approval: the Investigational New Drug (IND) application and the New Drug Application (NDA). Here’s an overview of these application types in India:

1. Investigational New Drug (IND) Application:
   • Purpose: The IND application in India is submitted to the CDSCO before conducting clinical trials on an investigational drug in humans.
   • Content: The IND application includes data from preclinical studies, information on the drug’s composition, manufacturing details, proposed clinical trial protocols, and any other relevant supporting data.
   • Review Process: The CDSCO reviews the IND application to assess the safety, efficacy, and quality aspects of the investigational drug. They evaluate the proposed clinical trial protocols and ensure the protection of human subjects participating in the trials.
   • IND Phases: The IND application goes through the same three phases as in the US: Phase 1, Phase 2, and Phase 3. Each phase involves progressively larger clinical trials to assess safety and efficacy.
   • IND Approval: If the CDSCO finds the proposed clinical trial protocols acceptable and deems the drug reasonably safe for human use, they grant approval to conduct the trials.
2. New Drug Application (NDA):
   • Purpose: The NDA in India is submitted to the CDSCO after the completion of clinical trials to request marketing approval for a new drug.
   • Content: The NDA includes comprehensive data on the drug’s preclinical and clinical studies, chemistry, manufacturing details, packaging information, proposed labeling, and safety and efficacy data.
   • Review Process: The CDSCO reviews the NDA to evaluate the safety, efficacy, and quality of the drug. They assess the submitted data, review the proposed labeling and indications, and conduct a thorough examination of the drug’s benefits and risks.
   • CDSCO Approval: If the CDSCO determines that the drug meets the necessary standards for safety, efficacy, and quality, they grant marketing approval, allowing the drug to be marketed and sold in India.
   • Post-Marketing Surveillance: After NDA approval, the CDSCO continues to monitor the drug’s safety and effectiveness through post-marketing surveillance and may take regulatory actions if any safety concerns arise.

It’s important to note that the specific requirements and procedures for IND and NDA applications in India may vary in detail compared to the United States. The CDSCO has its own guidelines and regulations governing the approval process, and applicants need to comply with Indian regulatory requirements for drug development and marketing authorization.

You may be interested in the programs below: